September 2019 – CARDiOmics Club

By Cardiomics Club 9 September, 201912 September, 2019

THEMIS trial: when significant is not significant

Fernando Botto – ESC 2019 hot line sessions delivered us enough evidence to discuss methods and patient-centered decisions. For instance, dual antiplatelet treatment came up with a new trial in … Continue reading THEMIS trial: when significant is not significant

By Cardiomics Club 7 September, 20198 September, 2019

Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned

Pablo Lamelas – One of the top surprises from ESC congress 2019 was ISAR-REACT 5 trial, which concluded that in acute coronary syndromes Prasugrel was superior to Ticagrelor for efficacy … Continue reading Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned

By Cardiomics Club 2 September, 20192 September, 2019

Reducing cardiovascular risk in hypertension – HOPE-4 Trial

Pablo Lamelas – Hypertension is the largest responsible of death in the world. Its control and risk reduction is a health priority, specially middle- and low-income countries where risk factor … Continue reading Reducing cardiovascular risk in hypertension – HOPE-4 Trial

By Cardiomics Club 1 September, 20192 September, 2019

Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?

Pablo Lamelas – Multiple small randomized trials evaluating the effect of complete revascularization in STEMI suggested that complete revascularization was associated with a marked reduction (50%) in cardiovascular death, as … Continue reading Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?